217 related articles for article (PubMed ID: 31498151)
1. Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma.
Bayles I; Krajewska M; Pontius WD; Saiakhova A; Morrow JJ; Bartels C; Lu J; Faber ZJ; Fedorov Y; Hong ES; Karnuta JM; Rubin B; Adams DJ; George RE; Scacheri PC
J Clin Invest; 2019 Oct; 129(10):4377-4392. PubMed ID: 31498151
[TBL] [Abstract][Full Text] [Related]
2. Macrophage migration inhibitory factor promotes osteosarcoma growth and lung metastasis through activating the RAS/MAPK pathway.
Wang C; Zhou X; Li W; Li M; Tu T; Ba X; Wu Y; Huang Z; Fan G; Zhou G; Wu S; Zhao J; Zhang J; Chen J
Cancer Lett; 2017 Sep; 403():271-279. PubMed ID: 28642171
[TBL] [Abstract][Full Text] [Related]
3. CDK12: an emerging therapeutic target for cancer.
Lui GYL; Grandori C; Kemp CJ
J Clin Pathol; 2018 Nov; 71(11):957-962. PubMed ID: 30104286
[TBL] [Abstract][Full Text] [Related]
4. CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
Johnson SF; Cruz C; Greifenberg AK; Dust S; Stover DG; Chi D; Primack B; Cao S; Bernhardy AJ; Coulson R; Lazaro JB; Kochupurakkal B; Sun H; Unitt C; Moreau LA; Sarosiek KA; Scaltriti M; Juric D; Baselga J; Richardson AL; Rodig SJ; D'Andrea AD; Balmaña J; Johnson N; Geyer M; Serra V; Lim E; Shapiro GI
Cell Rep; 2016 Nov; 17(9):2367-2381. PubMed ID: 27880910
[TBL] [Abstract][Full Text] [Related]
5. CDK12 Promotes Cervical Cancer Progression through Enhancing Macrophage Infiltration.
Yang B; Chen J; Teng Y
J Immunol Res; 2021; 2021():6645885. PubMed ID: 33628849
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the metastatic phenotype of a panel of established osteosarcoma cells.
Ren L; Mendoza A; Zhu J; Briggs JW; Halsey C; Hong ES; Burkett SS; Morrow J; Lizardo MM; Osborne T; Li SQ; Luu HH; Meltzer P; Khanna C
Oncotarget; 2015 Oct; 6(30):29469-81. PubMed ID: 26320182
[TBL] [Abstract][Full Text] [Related]
7. The promise and current status of CDK12/13 inhibition for the treatment of cancer.
Tadesse S; Duckett DR; Monastyrskyi A
Future Med Chem; 2021 Jan; 13(2):117-141. PubMed ID: 33295810
[TBL] [Abstract][Full Text] [Related]
8. CDK12 and PAK2 as novel therapeutic targets for human gastric cancer.
Liu H; Shin SH; Chen H; Liu T; Li Z; Hu Y; Liu F; Zhang C; Kim DJ; Liu K; Dong Z
Theranostics; 2020; 10(14):6201-6215. PubMed ID: 32483448
[No Abstract] [Full Text] [Related]
9. Upregulation of miR-328 and inhibition of CREB-DNA-binding activity are critical for resveratrol-mediated suppression of matrix metalloproteinase-2 and subsequent metastatic ability in human osteosarcomas.
Yang SF; Lee WJ; Tan P; Tang CH; Hsiao M; Hsieh FK; Chien MH
Oncotarget; 2015 Feb; 6(5):2736-53. PubMed ID: 25605016
[TBL] [Abstract][Full Text] [Related]
10. CDK12-mediated transcriptional regulation of noncanonical NF-κB components is essential for signaling.
Henry KL; Kellner D; Bajrami B; Anderson JE; Beyna M; Bhisetti G; Cameron T; Capacci AG; Bertolotti-Ciarlet A; Feng J; Gao B; Hopkins B; Jenkins T; Li K; May-Dracka T; Murugan P; Wei R; Zeng W; Allaire N; Buckler A; Loh C; Juhasz P; Lucas B; Ennis KA; Vollman E; Cahir-McFarland E; Hett EC; Ols ML
Sci Signal; 2018 Jul; 11(541):. PubMed ID: 30065029
[TBL] [Abstract][Full Text] [Related]
11. Th e role of CDK12 in tumor bio logy.
Dzimková M; Procházková J; Klát J; Kohoutek J
Klin Onkol; 2020; 33(4):260-267. PubMed ID: 32894954
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma.
Jiang B; Jiang J; Kaltheuner IH; Iniguez AB; Anand K; Ferguson FM; Ficarro SB; Seong BKA; Greifenberg AK; Dust S; Kwiatkowski NP; Marto JA; Stegmaier K; Zhang T; Geyer M; Gray NS
Eur J Med Chem; 2021 Oct; 221():113481. PubMed ID: 33945934
[TBL] [Abstract][Full Text] [Related]
13. Tegavivint and the β-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma.
Nomura M; Rainusso N; Lee YC; Dawson B; Coarfa C; Han R; Larson JL; Shuck R; Kurenbekova L; Yustein JT
J Natl Cancer Inst; 2019 Nov; 111(11):1216-1227. PubMed ID: 30793158
[TBL] [Abstract][Full Text] [Related]
14. MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma.
Pitolli C; Marini A; Guerra M; Pieraccioli M; Marabitti V; Palluzzi F; Giacò L; Tamburrini G; Cecconi F; Nazio F; Sette C; Pagliarini V
J Exp Clin Cancer Res; 2023 Aug; 42(1):214. PubMed ID: 37599362
[TBL] [Abstract][Full Text] [Related]
15. Targeting CDK12-mediated transcription regulation in anaplastic thyroid carcinoma.
Geng M; Yang Y; Cao X; Dang L; Zhang T; Zhang L
Biochem Biophys Res Commun; 2019 Dec; 520(3):544-550. PubMed ID: 31615655
[TBL] [Abstract][Full Text] [Related]
16. BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells.
Baker EK; Taylor S; Gupte A; Sharp PP; Walia M; Walsh NC; Zannettino AC; Chalk AM; Burns CJ; Walkley CR
Sci Rep; 2015 May; 5():10120. PubMed ID: 25944566
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.
Quereda V; Bayle S; Vena F; Frydman SM; Monastyrskyi A; Roush WR; Duckett DR
Cancer Cell; 2019 Nov; 36(5):545-558.e7. PubMed ID: 31668947
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 3-Benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors.
Ito M; Tanaka T; Toita A; Uchiyama N; Kokubo H; Morishita N; Klein MG; Zou H; Murakami M; Kondo M; Sameshima T; Araki S; Endo S; Kawamoto T; Morin GB; Aparicio SA; Nakanishi A; Maezaki H; Imaeda Y
J Med Chem; 2018 Sep; 61(17):7710-7728. PubMed ID: 30067358
[TBL] [Abstract][Full Text] [Related]
19. Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing.
Liang K; Gao X; Gilmore JM; Florens L; Washburn MP; Smith E; Shilatifard A
Mol Cell Biol; 2015 Mar; 35(6):928-38. PubMed ID: 25561469
[TBL] [Abstract][Full Text] [Related]
20. BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors.
Paculová H; Kramara J; Šimečková Š; Fedr R; Souček K; Hylse O; Paruch K; Svoboda M; Mistrík M; Kohoutek J
Tumour Biol; 2017 Oct; 39(10):1010428317727479. PubMed ID: 29025359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]